In the 1950s, doctors Carlton Gajdusek and Vincent Zigas trekked over mountains and across rivers to study a mysterious and fatal neurological disease called…
In 2022, more Canadians died by medical euthanasia than from pneumonia, Alzheimer’s, or liver disease. The Quebec government announced in October that people with…
Athira Pharma, makers of experimental Alzheimer’s drug fosgonimeton, paid up $4 million to settle a federal case following allegations that the company manipulated scientific…
In addition to warmer, drier, more extreme weather, climate change is also causing more active wildfire seasons, and that means more exposure to wildfire…
Mild cognitive impairment and dementia can bring insomnia and other sleep issues. Here are the sleep aids that aren’t considered safe — and eight…
Since their discovery in the 1960s, stem cells have captivated our curiosity. Unlike other cells in the body, stem cells are changeable — they…
This month, the U.S. Senate passed the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Reauthorization Act of 2024. Originally signed into law in…
After a hack exposed the data of millions of its customers, the at-home genetic testing giant 23andMe has faced financial difficulties and may now…
An international group of researchers is challenging the controversial new definition of Alzheimer’s proposed by a group of researchers convened by the Alzheimer’s Association….
A recent Science investigation found that Eliezer Masliah, one of the world’s leading Alzheimer’s and Parkinson’s researchers, engaged in research misconduct over the course…
Before 1993, researchers seldom included women in clinical trials. And yet, women have dramatically different risk of health conditions than men do. For example,…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
For decades, scientists blamed Alzheimer’s disease on the buildup of beta-amyloid protein plaques in the brain. But most clinical trials for drugs intended to…
On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial….
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…